GRK2 and atherosclerosis: OSS increases the expression level of GRK2S29p, and the use of vascular endothelial cell‐specific GRK2 knockout mice and chemical GRK2 inhibitors further supports the potential of targeting GRK2 as a therapeutic strategy for atherosclerosis.